严重创伤ECMO使用的挑战:叙事审查
Xin-Liang Zhang1, Ying-Qi Zhang1, Zhi-Yong Hou2
1Emergency Department, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050051, China.
Hereditas
|November 22, 2025
概括
身体外膜氧化 (ECMO) 为严重创伤患者提供关键支持,这些患者面临呼吸或循环功能衰竭. 需要进一步的研究和标准化的协议来优化创伤ECMO管理的结果和个性化护理.
科学领域:
- 关键护理医学 关键护理医学
- 创伤外科 手术 创伤外科
- 支持心肺血管的支持.
背景情况:
- 严重创伤患者面临急性呼吸衰竭和循环系统崩的高风险.
- 当传统疗法不足时,体外膜氧化 (ECMO) 是一种至关重要的支持.
- 本综述探讨了ECMO在严重创伤中的作用,包括其用途,挑战和未来前景.
研究的目的:
- 分析ECMO在严重创伤患者的临床应用.
- 专注于ECMO在创伤护理中的指示,并发症,预后因素和未来方向.
主要方法:
- 对2000年1月至2025年4月的研究进行了全面的文献搜索.
- 包括的来源包括原始研究,评论,元分析,临床指南和专家共识.
- 重点是ECMO在创伤护理机构中的应用.
主要成果:
- 静脉ECMO用于创伤相关的ARDS;静脉动脉ECMO用于心脏性休克/心脏骤停.
- 存活率:VV-ECMO的72.3%,VA-ECMO的39.0%. 这是一个很好的例子.
- 并发症包括感染,出血,血栓;预后工具是有限的,缺乏创伤特定的模型.
结论:
- 对于严重创伤患者来说,ECMO是一种有价值的支持性疗法.
- 改善结果需要创伤特定的决策工具和多中心研究.
- 对抗凝血和感染控制的标准化方案对于个性化护理至关重要.
相关概念视频
Pulmonary Embolism I: Introduction
457
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
457
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
267
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
267
Pulmonary Embolism III: Nursing Management
311
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
311
Acute Respiratory Failure-II
974
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
974
Cardiopulmonary Resuscitation IV: Pharmacological Management
561
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
561
Flail Chest-II
484
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
484


